A trial looking at 32P BioSilicon during chemotherapy for advanced pancreatic cancer

Cancer type:

Pancreatic cancer




Phase 2

This trial looked at treatment for advanced pancreatic cancer using injections of silicon with a radioactive substance attached.

Doctors can use chemotherapy to treat advanced pancreatic cancer. Gemcitabine was the chemotherapy drug they already used at the time of this trial.

In this trial, researchers were looking at a new treatment called 32P BioSilicon. This is made of small particles of silicon attached to radioactive phosphorus. Doctors injected the silicon particles directly into the tumour. The aim of the treatment was to kill off any cancer cells nearby.

The researchers were testing 2 different doses of 32P BioSilicon. People had this treatment as well as having chemotherapy.

The aims of the trial were to

  • See if 32P BioSilicon helped people with advanced pancreatic cancer
  • Find the best dose to use
  • Learn more about the side effects

Summary of results

The research team found that 32P BioSilicon was well tolerated and safe to give to people with advanced pancreatic cancer.

This trial recruited 6 people. The first 3 people had a low dose of 32P BioSilicon. As there were no serious side effects, the next 3 people had a higher dose.

For all 6 people, their cancer growth was stopped.

There were no complications at the time of giving 32P BioSilicon. During follow up no major side effects were reported.

The research team concluded that 32P BioSilicon is a safe and well tolerated treatment for people with advanced pancreatic cancer.

We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Paul Ross

Supported by

Experimental Cancer Medicine Centre (ECMC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 1774

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think